These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 19414316

  • 1. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M, Wada J, Suzuki H, Tanaka M, Katano M, Morisaki T.
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [Abstract] [Full Text] [Related]

  • 2. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H, Yamaguchi Y.
    Cancer; 1997 Jul 01; 80(1):42-9. PubMed ID: 9210707
    [Abstract] [Full Text] [Related]

  • 3. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer.
    Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S.
    Br J Surg; 2000 Jan 01; 87(1):43-8. PubMed ID: 10606909
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
    Abdel-Wahab M, El-Shennawy F, Agha S, Ragab E, Fathi O, Sultan A, Elghawalby N, Ezzat F.
    Hepatogastroenterology; 1999 May 01; 46 Suppl 1():1293-6. PubMed ID: 10429977
    [Abstract] [Full Text] [Related]

  • 5. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
    Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M.
    Pancreas; 2012 Mar 01; 41(2):195-205. PubMed ID: 21792083
    [Abstract] [Full Text] [Related]

  • 6. The role of circulating dendritic cells in patients with unresectable pancreatic cancer.
    Hirooka S, Yanagimoto H, Satoi S, Yamamoto T, Toyokawa H, Yamaki S, Yui R, Inoue K, Michiura T, Kwon AH.
    Anticancer Res; 2011 Nov 01; 31(11):3827-34. PubMed ID: 22110205
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.
    Oncologist; 2009 Oct 01; 14(10):995-1002. PubMed ID: 19776094
    [Abstract] [Full Text] [Related]

  • 8. Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience.
    Gardini A, Morgagni P, Milandri C, Riccobon A, Ridolfi R, La Barba G, Saragoni L, Amadori D, Garcea D.
    Hepatogastroenterology; 2012 May 01; 59(115):687-90. PubMed ID: 22469709
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM, Sugarbaker PH.
    Cancer Detect Prev; 1990 May 01; 14(4):483-90. PubMed ID: 2224911
    [Abstract] [Full Text] [Related]

  • 10. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy.
    Ohguri T, Imada H, Nomoto S, Yahara K, Hisaoka M, Hashimoto H, Tokura Y, Nakamura K, Shioyama Y, Honda H, Terashima H, Moroi Y, Furue M, Korogi Y.
    Int J Radiat Oncol Biol Phys; 2005 Apr 01; 61(5):1446-53. PubMed ID: 15817349
    [Abstract] [Full Text] [Related]

  • 11. EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer.
    Yamamoto K, Shimada S, Hirota M, Yagi Y, Matsuda M, Baba H.
    Int J Oncol; 2005 Nov 01; 27(5):1321-8. PubMed ID: 16211228
    [Abstract] [Full Text] [Related]

  • 12. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
    Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):878-87. PubMed ID: 16467102
    [Abstract] [Full Text] [Related]

  • 13. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, Yahara N, Yoshino S, Hazama S.
    Oncol Rep; 2008 Jul 01; 20(1):155-63. PubMed ID: 18575732
    [Abstract] [Full Text] [Related]

  • 14. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
    Brouquet A, Goéré D, Lefèvre JH, Bonnet S, Dumont F, Raynard B, Elias D.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2744-51. PubMed ID: 19626375
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic hepatic irradiation following curative resection of pancreatic cancer.
    Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Inoue K, Katano S, Tsukiyama I.
    J Hepatobiliary Pancreat Surg; 2005 Oct 01; 12(3):235-42. PubMed ID: 15995813
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
    Morisaki T, Matsumoto K, Kuroki H, Kubo M, Baba E, Onishi H, Tasaki A, Nakamura M, Inaba S, Katano M.
    Anticancer Res; 2003 Oct 01; 23(6a):4459-65. PubMed ID: 14666734
    [Abstract] [Full Text] [Related]

  • 18. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
    Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y.
    Cancer; 2008 Nov 01; 113(9):2518-23. PubMed ID: 18780323
    [Abstract] [Full Text] [Related]

  • 19. [Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination].
    Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Tamai M, Taniguchi K, Aoki Y.
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug 20; 25(8):1558-64. PubMed ID: 2172423
    [Abstract] [Full Text] [Related]

  • 20. Unresectable pancreatic cancer: is a multi-modality approach a promising therapeutical alternative?
    Lygidakis NJ, Dedemati G, Spenzaris N, Theodoropoulou M.
    Hepatogastroenterology; 1997 Aug 20; 44(16):1222-8. PubMed ID: 9261631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.